Taken together, our findings show that FGF-2 is highly expressed in NPC xenografts and NPC clinical samples, and provide a mechanistic explanation of the intrinsic AAD resistance mediated through FGF-2-FGFR1-MAPK-MYC signaling. Here, FGFR1 is linked to nasopharyngeal carcinoma.